Figure 2 Ischaemic and bleeding outcomes in the major clinical trials comparing bivalirudin versus heparin in ST-segment elevation myocardial infarction (STEMI) Figure 2 | Ischaemic and bleeding outcomes in the major clinical trials comparing bivalirudin versus heparin in ST-segment elevation myocardial infarction (STEMI). The graphs show relative risk with the 95% confidence intervals of bivalirudin versus heparin on a | major adverse cardiovascular events (MACE) and b | major bleeding. MACE and major bleeding are as defined in each study protocol. Follow-up was 30 days for each trial, with the exception of HEAT-PPCI for which it was 28 days. *Data are reported for the comparisons between bivalirudin versus heparin plus bailout glycoprotein IIb/IIIa inhibitors. ‡The MATRIX trial included 7,213 patients with acute coronary syndrome for whom percutaneous coronary intervention was anticipated, of whom 4,010 (56%) had STEMI and 3,203 (44%) non-ST-segment elevation acute coronary syndrome. The results of the STEMI subgroup are reported here. Franchi, F. et al. (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI Nat. Rev. Cardiol. doi:10.1038/nrcardio.2017.18